Phesgo and Tecentriq Performance and Approvals
Changes to the development pipeline
Q1 2023 update
New to phase III
RG6149 astegolimab (Anti-ST2) - COPD
New to phase I
New to phase II
1AI:
2 NMES:
1 NME:
RG6107 crovalimab - lupus nephritis
RG6501 OpRegen - geographic atrophy
RG6341 NME- chronic cough
1 Al:
1 Al:
RG6237 latent myostatin - FSHD
RG7159 Gazyva - pediatric nephrotic
syndrome
Removed from phase I
Removed from phase II
Removed from phase III
3 NMES:
1 NME:
2 Als:
RG6129 HLA-A2-MAGE-A4 x CD3 - solid
tumors
RG6354 zinpentraxin alfa (PRM-151) -
myelofibrosis
RG6290 MAGE-A4 ImmTAC - solid tumors
RG6312 NME - geographic atrophy
Status as of April 26, 2023
Roche
New to registration
Approvals
RG7446 Tecentriq + cabozantinib - RCC adv
RG7446 Tecentriq + paclitaxel - TNBC adj
1 AI (US):
RG7596 Polivy - 11 DLBCL
NME approval in other territory than US
and EU:
RG6026 Columvi (glofitamab) - 3L+ DLBCL
(First approved in Canada)
I
I
52
52View entire presentation